PERSPECTIVE THERAPEUTICS, INC.
Income Statement
| Line Item | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $0 | $10.1M | $9.7M | $7.3M | $5.9M | $4.8M | $4.8M |
| Cost of Revenue | — | $6.2M | $4.9M | $4.6M | $4.3M | $4.1M | $3.9M | $4.6M |
| Gross Profit | $1.4M | $0 | $5.1M | $5.1M | $3.0M | $1.8M | $838.0K | $129.0K |
| Gross Margin | 100.0% | — | 50.9% | 52.9% | 41.7% | 31.1% | 17.6% | 2.7% |
| Operating Expenses | ||||||||
| Research & Development | $21.3M | $881.0K | $1.4M | $1.1M | $1.5M | $1.7M | $965.0K | $528.0K |
| SG&A Expense | $21.1M | $7.5M | $4.7M | $4.6M | $4.2M | $4.2M | $3.9M | $3.8M |
| Operating Income | $-40.9M | $-8.7M | $-3.4M | $-3.5M | $-5.3M | $-6.7M | $-6.3M | $-5.1M |
| Operating Margin | -2,855.0% | — | -34.3% | -35.9% | -71.8% | -113.6% | -132.5% | -106.6% |
| Interest Expense | $84.0K | $0 | — | — | — | — | $0 | $1.0K |
| Pretax Income | $-40.1M | $-8.1M | — | — | — | — | — | — |
| Income Tax Expense | $-2.7M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-46.5M | $-10.8M | $-3.4M | $-3.4M | $-5.1M | $-6.7M | $-6.2M | $-4.7M |
| Net Margin | -3,243.2% | — | -33.7% | -35.6% | -70.3% | -113.1% | -129.4% | -98.8% |
| EPS (Basic) | $-0.87 | $-0.04 | $-0.02 | $-0.03 | $-0.04 | $-0.06 | $-0.06 | $-0.05 |
| EPS (Diluted) | $-0.87 | — | $-0.02 | $-0.03 | $-0.04 | $-0.06 | $-0.06 | $-0.05 |
| Shares Outstanding (Basic) | 53.5M | 284.1M | 207.7M | 135.2M | 134.8M | 134.7M | 110.0M | 110.0M |
| Shares Outstanding (Diluted) | 53.5M | 284.1M | 207.7M | 135.2M | 134.8M | 134.7M | 110.0M | 110.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |